부산대학교 도서관

Based on the patient's clinical stability and the absence of new lesions in the last two brain MRIs, maintaining the patient without any disease-modifying treatment was decided. Dear Sirs, Progressive multifocal leukoencephalopathy (PML) is an opportunistic demyelinating disease leading to disability or being sometimes fatal, and it is caused by the reactivation of a latent John Cunningham virus (JCV) infection in patients whose cellular immune system is compromised [[1]]. We decided to treat our patient with filgrastim or granulocyte-colony stimulating factor G-CSF, as patients with PML secondary to natalizumab showed a good response after this treatment [[4]]. In studies that analysed patients with natalizumab-associated PML, those patients who were asymptomatic and with a more localized disease on MRI at diagnosis had a better prognosis with improved survival rates and less functional disability [[6]]. [Extracted from the article]